EPIX REPORTS FIRST QUARTER 2006 RESULTS

Epix Pharmaceuticals, Inc., a developer of innovative pharmaceuticals for magnetic resonance imaging (MRI), today announced results for the first quarter 2006. Financial highlights for the quarter ended March 31, 2006 included: Net loss of $4.5 million, or $0.19 per share, in the first quarter of 2006 compared to a net loss of $6.3 million, or $0.27 per share, for the first quarter of 2005.
Genetic Engineering News